CL2017002155A1 - Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos - Google Patents
Derivados de nucleósidos sustituidos útiles como agentes antineoplásicosInfo
- Publication number
- CL2017002155A1 CL2017002155A1 CL2017002155A CL2017002155A CL2017002155A1 CL 2017002155 A1 CL2017002155 A1 CL 2017002155A1 CL 2017002155 A CL2017002155 A CL 2017002155A CL 2017002155 A CL2017002155 A CL 2017002155A CL 2017002155 A1 CL2017002155 A1 CL 2017002155A1
- Authority
- CL
- Chile
- Prior art keywords
- antineoplastic agents
- derivatives useful
- substituted nucleoside
- nucleoside derivatives
- compounds
- Prior art date
Links
- 229940034982 antineoplastic agent Drugs 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119932P | 2015-02-24 | 2015-02-24 | |
| US201562213801P | 2015-09-03 | 2015-09-03 | |
| US201662279209P | 2016-01-15 | 2016-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002155A1 true CL2017002155A1 (es) | 2018-05-11 |
Family
ID=55451515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002155A CL2017002155A1 (es) | 2015-02-24 | 2017-08-24 | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10428104B2 (enExample) |
| EP (1) | EP3262057B1 (enExample) |
| JP (1) | JP6584521B2 (enExample) |
| KR (1) | KR20170119705A (enExample) |
| CN (1) | CN107278205A (enExample) |
| AU (2) | AU2016225133B2 (enExample) |
| BR (1) | BR112017017396A2 (enExample) |
| CA (1) | CA2921314A1 (enExample) |
| CL (1) | CL2017002155A1 (enExample) |
| CO (1) | CO2017008403A2 (enExample) |
| CR (1) | CR20170384A (enExample) |
| CU (1) | CU20170105A7 (enExample) |
| DO (1) | DOP2017000195A (enExample) |
| EA (1) | EA031895B1 (enExample) |
| ES (1) | ES2792899T3 (enExample) |
| GT (1) | GT201700189A (enExample) |
| IL (1) | IL253637A0 (enExample) |
| MX (1) | MX2017010844A (enExample) |
| NI (1) | NI201700095A (enExample) |
| PE (1) | PE20171449A1 (enExample) |
| PH (1) | PH12017501413A1 (enExample) |
| SG (1) | SG11201706050WA (enExample) |
| SV (1) | SV2017005514A (enExample) |
| TN (1) | TN2017000357A1 (enExample) |
| TW (1) | TWI622595B (enExample) |
| UA (1) | UA118315C2 (enExample) |
| UY (1) | UY36564A (enExample) |
| WO (1) | WO2016135582A1 (enExample) |
| ZA (1) | ZA201705092B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| CN108884108B (zh) | 2016-03-10 | 2021-08-31 | 詹森药业有限公司 | 用于用作prmt5抑制剂的取代核苷类似物 |
| US10898504B2 (en) | 2016-03-10 | 2021-01-26 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| AU2017326487B2 (en) | 2016-09-14 | 2021-08-05 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| BR112019006414A2 (pt) * | 2016-10-03 | 2019-06-25 | Janssen Pharmaceutica Nv | análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5 |
| KR102513564B1 (ko) | 2016-12-15 | 2023-03-22 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 아제판 억제제 |
| WO2018152501A1 (en) * | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018152548A1 (en) * | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| SG11201907607VA (en) | 2017-02-27 | 2019-09-27 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
| WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| MA49840A (fr) * | 2017-08-09 | 2020-06-17 | Prelude Therapeutics Inc | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| EP3700906A1 (en) * | 2017-10-26 | 2020-09-02 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| MX2020005944A (es) * | 2017-12-08 | 2020-08-24 | Janssen Pharmaceutica Nv | Analogos espirobiciclicos novedosos. |
| CR20200263A (es) | 2017-12-13 | 2020-07-26 | Lupin Ltd | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CA3092357A1 (en) * | 2018-03-14 | 2019-09-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| WO2020033285A1 (en) * | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US20220160713A1 (en) * | 2019-02-13 | 2022-05-26 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) |
| EP3947387B1 (en) * | 2019-03-25 | 2024-10-23 | California Institute Of Technology | Prmt5 inhibitors and uses thereof |
| WO2020206299A1 (en) | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| CR20220010A (es) | 2019-06-10 | 2022-05-13 | Lupin Ltd | Inhibidores de prmt5 |
| PH12021553075A1 (en) | 2019-06-12 | 2023-09-11 | Janssen Pharmaceutica Nv | Novel spirobicyclic intermediates |
| SI4299135T1 (sl) | 2019-06-18 | 2025-12-31 | Pfizer Inc. | Benzizoksazolni sulfonamidni derivati |
| CA3154566A1 (en) | 2019-09-18 | 2021-03-25 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| GEP20247638B (en) | 2019-10-22 | 2024-07-10 | Lupin Ltd | Pharmaceutical combination of prmt5 inhibitors |
| EP4069698A1 (en) | 2019-12-03 | 2022-10-12 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
| IL300555A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a JAK inhibitor |
| CA3192055A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
| US20240101589A1 (en) * | 2020-10-08 | 2024-03-28 | Strom Therapeutics Limited | Inhibitors of mettl3 |
| CN112679505B (zh) * | 2020-12-25 | 2022-04-22 | 杭州澳赛诺生物科技有限公司 | 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法 |
| WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
| CA3226714A1 (en) | 2021-07-12 | 2023-01-19 | Incyte Corporation | Process and intermediates for preparing baricitinib |
| WO2023017152A1 (en) * | 2021-08-13 | 2023-02-16 | Albert-Ludwigs-Universität Freiburg | Specific small molecule inhibitors that block kmt9 methyltransferase activity and function |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| WO2026008533A1 (en) | 2024-07-01 | 2026-01-08 | Janssen Pharmaceutica Nv | Prmt5 inhibitors for treating adenomas |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646128A (en) * | 1989-09-15 | 1997-07-08 | Gensia, Inc. | Methods for treating adenosine kinase related conditions |
| US5864033A (en) * | 1989-09-15 | 1999-01-26 | Metabasis Therapeutics, Inc. | Adenosine kinase inhibitors |
| US5795977A (en) * | 1989-09-15 | 1998-08-18 | Metabasis Therapeutics, Inc. | Water soluble adenosine kinase inhibitors |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9813554D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| US6831069B2 (en) * | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| AU2003263846B2 (en) * | 2002-08-15 | 2009-12-17 | Gilead Palo Alto, Inc. | Partial and full agonists of A1 adenosine receptors |
| WO2010108140A1 (en) * | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| WO2013009735A1 (en) * | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| US8575119B2 (en) * | 2011-09-23 | 2013-11-05 | Enanta Pharmaceuticals, Inc. | 2′-chloroacetylenyl substituted nucleoside derivatives |
| WO2015200680A2 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| AR104326A1 (es) * | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| AU2016301188A1 (en) * | 2015-08-06 | 2018-02-15 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
-
2016
- 2016-02-15 EA EA201791563A patent/EA031895B1/ru not_active IP Right Cessation
- 2016-02-15 TN TNP/2017/000357A patent/TN2017000357A1/en unknown
- 2016-02-15 UA UAA201708102A patent/UA118315C2/uk unknown
- 2016-02-15 WO PCT/IB2016/050803 patent/WO2016135582A1/en not_active Ceased
- 2016-02-15 CR CR20170384A patent/CR20170384A/es unknown
- 2016-02-15 SG SG11201706050WA patent/SG11201706050WA/en unknown
- 2016-02-15 PE PE2017001447A patent/PE20171449A1/es unknown
- 2016-02-15 BR BR112017017396A patent/BR112017017396A2/pt not_active Application Discontinuation
- 2016-02-15 CN CN201680011823.1A patent/CN107278205A/zh active Pending
- 2016-02-15 ES ES16707209T patent/ES2792899T3/es active Active
- 2016-02-15 JP JP2017544584A patent/JP6584521B2/ja not_active Expired - Fee Related
- 2016-02-15 EP EP16707209.9A patent/EP3262057B1/en active Active
- 2016-02-15 KR KR1020177026762A patent/KR20170119705A/ko not_active Ceased
- 2016-02-15 MX MX2017010844A patent/MX2017010844A/es unknown
- 2016-02-15 CU CUP2017000105A patent/CU20170105A7/xx unknown
- 2016-02-15 AU AU2016225133A patent/AU2016225133B2/en not_active Ceased
- 2016-02-17 US US15/045,679 patent/US10428104B2/en active Active
- 2016-02-19 CA CA2921314A patent/CA2921314A1/en not_active Abandoned
- 2016-02-19 TW TW105104968A patent/TWI622595B/zh not_active IP Right Cessation
- 2016-02-22 UY UY0001036564A patent/UY36564A/es not_active Application Discontinuation
-
2017
- 2017-07-24 IL IL253637A patent/IL253637A0/en unknown
- 2017-07-26 ZA ZA2017/05092A patent/ZA201705092B/en unknown
- 2017-07-28 NI NI201700095A patent/NI201700095A/es unknown
- 2017-08-08 PH PH12017501413A patent/PH12017501413A1/en unknown
- 2017-08-14 SV SV2017005514A patent/SV2017005514A/es unknown
- 2017-08-17 CO CONC2017/0008403A patent/CO2017008403A2/es unknown
- 2017-08-21 DO DO2017000195A patent/DOP2017000195A/es unknown
- 2017-08-24 CL CL2017002155A patent/CL2017002155A1/es unknown
- 2017-08-24 GT GT201700189A patent/GT201700189A/es unknown
-
2018
- 2018-12-11 AU AU2018278842A patent/AU2018278842A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017008403A2 (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| CO2018013105A2 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| PY1906086A (es) | Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer | |
| CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
| CU20180027A7 (es) | DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| CR20190566A (es) | Inhibidores de quinasay usos de los mismos | |
| CU20180001A7 (es) | Derivados de oxopiridina sustituidos y procesos para su preparación | |
| CR20180057A (es) | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. | |
| CR20170564A (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| CR20180072A (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| CU20170164A7 (es) | Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen | |
| ECSP17069696A (es) | Compuestos novedosos | |
| CO2018004581A2 (es) | Compuestos de criptoficina y productos conjugados, y sus métodos de preparación | |
| CU24309B1 (es) | Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen | |
| CL2017000151A1 (es) | Derivados de piridona | |
| MX2017008373A (es) | Compuestos, composiciones y metodos. | |
| PY1735113A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| ECSP17063489A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos |